araag2/HINT huggingface dataset:
Clinical trial NCT01120093 (phase 2, status: completed)
Conditions: chronic obstructive pulmonary disease (copd)
ICD codes: G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, N13.8
Drugs: aclidinium bromide 100 μg bid, aclidinium bromide 200 μg bid, aclidininum bromide 400 μg bid, placebo, formoterol 12 μg bid
SMILES: OC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1, OC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Males and non-pregnant, non-lactating females aged ≥ 40.

          2. Patients with a clinical diagnosis of stable moderate to severe COPD, according to the
             Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines:
             (http://www.goldcopd.com) and stable airway obstruction. Post-salbutamol FEV1/FVC <
             70% at Screening Visit (Visit 1) (i.e., 100xpost-salbutamol FEV1/FVC <70%).

          3. Current, or ex-cigarette smoker with a smoking history of at least 10 pack-years.

          4. Patient whose FEV1 at the Screening Visit measured between 10-15 minutes post
             inhalation of salbutamol is 30% < FEV1 <80% of the predicted normal value (i.e., 100 x
             Post-salbutamol FEV1/ Predicted FEV1 must be < 80% and ≥ 30%).

          5. Female patients at least 1 year post-menopausal, surgically sterile (defined as having
             a hysterectomy or tubal ligation), or practicing a medically approved and highly
             effective method of contraception.

          6. Patients who understand the study procedures and are willing to participate in the
             study as indicated by signing the informed consent.

        Exclusion Criteria:

          1. History or current diagnosis of asthma.

          2. Clinically significant respiratory conditions other than COPD at the time of Inform
             Consent signature

          3. Hospitalisation due to COPD exacerbation within the previous 3 months.

          4. Signs of a COPD exacerbation or respiratory infection (including the upper respiratory
             tract) within the previous 6 weeks.

          5. Clinically significant cardiovascular conditions

          6. Presence of symptomatic prostatic hypertrophy and/or bladder neck obstruction.

          7. Presence of narrow-angle glaucoma.

          8. QTcB) above 470 milliseconds in the ECG performed at Screening Visit,

          9. Patient who does not maintain regular day/night, waking/sleeping cycles
Clinical trial NCT00618501 (phase 2, status: completed)
Conditions: leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: cytarabine, daunorubicin hydrochloride, etoposide, imatinib mesylate, leucovorin calcium, methotrexate, prednisolone, therapeutic hydrocortisone, vincristine sulfate
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1, NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, [H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Acute lymphoblastic leukemia (ALL) or acute mixed lineage leukemia

               -  Newly diagnosed disease

               -  Philadelphia-chromosome positive (Ph+) acute lymphoblastic leukemia or Ph+ acute
                  mixed lineage leukemia

                    -  Positive result for RT-PCR for Bcr-Abl transcript (Ph+ ALL or
                       Philadelphia-chromosome positive acute mixed lineage leukemia)

        PATIENT CHARACTERISTICS:

          -  Bilirubin < 2 mg/dL

          -  SGOT < 3 times upper limit of normal

          -  Creatinine < 2.0 mg/dL

          -  Ejection fraction > 45% by MUGA scan

          -  Not nursing

          -  Fertile patients must use effective contraception

          -  No known sensitivity to study drugs

          -  No severe medical conditions that, in the view of the investigator, prohibits
             participation in the study

        PRIOR CONCURRENT THERAPY:

          -  No other investigational agents in the past 30 days
Clinical trial NCT01073813 (phase 2, status: terminated)
Conditions: multiple sclerosis, optic neuritis
ICD codes: G35, C81.18, H46.8, H46.9
Drugs: minocycline
SMILES: [H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O
Reason stopped: 
    lack of recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Age between 18 and 60 years, the lower age limit has been set for safety purposes to
             avoid exposing children and adolescents to unproven therapies at least early in their
             development, the upper limit is set because the specificity of the diagnosis of ON is
             likely reduced in older individuals

          -  onset of ON within the previous 30 days

          -  intention to continue current multiple sclerosis (MS) disease modifying therapy (if
             any) for at least 6 months (glatiramer acetate, interferon beta) and not start, or
             switch to, a new therapy

          -  sexually active participants of child-bearing potential must agree to use adequate
             contraception

          -  willingness to provide written informed consent

        Exclusion Criteria:

          -  Coexistence of any disease other than MS that could be responsible for ON or better
             explains their signs and symptoms. This would include patients with other suspected or
             established causes of vision loss including glaucoma, maculopathies, amblyopia,
             neuro-myelitis optica (NMO), and other optic neuropathies

          -  clinically significant liver, renal, or bone marrow dysfunction

          -  any condition that could interfere with any evaluation in the study including patients
             who are unable to undergo reliable OCT testing due to dense media opacities or severe
             nystagmus in whom appropriate fixation cannot be attained

          -  concurrent or prior use of corticosteroids during this episode of optic neuritis

          -  concurrent participation in any clinical therapeutic trial

          -  use within the previous 12 months of any of the following: natalizumab, mitoxantrone,
             cyclophosphamide, azathioprine, cyclosporine, methotrexate, or any other
             immunomodulating or immunosuppressive drug including other recombinant or
             non-recombinant cytokine or any experimental therapy known to effect immune function

          -  use within the previous 6 months of minocycline or another tetracycline or use of
             either for MS at any time

          -  any other condition or situation that in the opinion of the investigator would either
             put the patient at risk of worsening health if enrolled in the trial or would prevent
             completion of the trial with complete follow-up.
Clinical trial NCT00384176 (phase 2/phase 3, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: cediranib, bevacizumab, 5-fluorouracil ( in folfox), leucovorin (in folfox), oxaliplatin (in folfox)
SMILES: COC1=CC2=C(C=C1OCCCN1CCCC1)N=CN=C2OC1=C(F)C2=C(NC(C)=C2)C=C1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, FC1=CNC(=O)NC1=O, [H]C(=O)N1C(CNC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNC2=C1C(=O)NC(N)=N2, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical Diagnosis of colon or rectal cancer

          -  No prior systemic therapy for metastatic disease. Any adjuvant/neoadjuvant oxaliplatin
             therapy must have been received >12 months prior to study entry and
             adjuvant/neoadjuvant 5-FU must have been received >6 months prior to study entry.

        Exclusion Criteria:

          -  Prior treatment with a VEGF Inhibitor, including bevacizumab and cediranib.

          -  Poorly controlled hypertension
Clinical trial NCT00737360 (phase 2, status: terminated)
Conditions: head and neck cancer
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11
Drugs: tas-106
SMILES: NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@](O)(C#C)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Age 18 ≤ years old at study entry

          -  Histologically confirmed head and neck carcinoma

          -  Received prior platinum based regimen and developed disease progression or recurrence

          -  Measurable disease according to RECIST guidelines

        Exclusion Criteria:

          -  Radiological or clinical evidence of brain involvement or leptomeningeal disease

          -  ≥ grade 2 peripheral neuropathy

          -  History of another malignancy
Clinical trial NCT00124280 (phase 2, status: completed)
Conditions: non-small-cell lung carcinoma
ICD codes: D02.20, D02.21, D02.22
Drugs: rad001
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with advanced (unresectable or metastatic) NSCLC

          -  Tissue sample of the metastatic or primary tumor available for pathology evaluation
             and molecular marker analyses

          -  Patients who have received ≤ 2 chemotherapy regimens, one of which must have included
             cisplatinum or carboplatin, and who have documented evidence of tumor progression (Arm
             1)

          -  Patients who have received ≤ 2 chemotherapy regimens, one of which must have included
             cisplatinum or carboplatin as well as a small molecule EGFR inhibitor (as a separate
             regimen) with documented tumor progression despite at least 4 weeks therapy with
             either gefitinib or erlotinib (Arm 2)

        Exclusion Criteria:

          -  Concurrent therapy with agents used otherwise as anticancer therapy (for example,
             methotrexate for rheumatoid arthritis)

          -  Any investigational drug, other than EGFR inhibitor (Arm 2), within the preceding 4
             weeks

          -  Chronic treatment with steroids or another immunosuppressive agent

          -  Uncontrolled brain or leptomeningeal metastases, including patients who continue to
             require glucocorticoids for brain or leptomeningeal metastases

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00461786 (phase 2, status: completed)
Conditions: ovarian cancer, peritoneal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, K65.1, K66.0, N99.4, N73.6, R88.0, Z49.32, Z49.02
Drugs: pemetrexed
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed recurrent or persistent disease ovarian epithelial or primary
             peritoneal cancer

          -  Measurable disease

          -  Must have received 1 prior platinum-based (carboplatin, cisplatin, or another
             organoplatinum compound) chemotherapy regimen for primary disease. Patients who had
             not received prior paclitaxel may have received a second regimen that included
             paclitaxel

          -  Treatment-free interval < 6 months after prior platinum-based therapy OR progressed
             during platinum-based therapy

          -  Not eligible for a higher priority Gynecologic Oncology Group (GOG) protocol (i.e.,
             any active phase III GOG protocol for the same patient population)

        Exclusion Criteria:

          -  Patients who have had prior therapy with pemetrexed

          -  Patients with a history of other invasive malignancies, with the exception of
             non-melanoma skin cancer, are excluded if there is any evidence of other malignancy
             being present within the last five years. Patients are also excluded if their previous
             cancer treatment contraindicates this protocol therapy.

          -  Patients who have received radiation to more than 25% of marrow
Clinical trial NCT00715676 (phase 2, status: completed)
Conditions: osteoporosis
ICD codes: M81.6, Z82.62, Z13.820, M81.8, Z87.310, M81.0, M80.80XS
Drugs: placebo, dp001
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Postmenopausal female subjects, defined as amenorrheic for at least 5 years

          -  Body Mass Index of 18 to 35

          -  Osteopenic

          -  Generally healthy

          -  Informed consent

        Exclusion Criteria

          -  History or evidence of acute or unstable chronic hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, psychiatric, or neurologic diseases

          -  Current or recent treatment with any medications or products affecting vitamin D
             metabolism, calcium balance, bone turnover, or an investigational drug therapy

          -  12-lead electrocardiogram demonstrating QTc (QT interval corrected for heart rate)
             >450 milliseconds at screening

          -  Abnormal creatinine clearance

          -  Elevated urinary calcium levels

          -  Vitamin D deficiency

          -  Excessive dietary calcium or vitamin D intake

          -  Current use of any illicit drug and/or history of alcohol abuse
Clinical trial NCT00617526 (phase 2, status: completed)
Conditions: hiv infections
ICD codes: Z21
Drugs: rdea806 400 mg, placebo, rdea806 1000 mg, rdea806 600 mg, rdea806 800 mg
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Documented chronic HIV-1 infection

          -  HIV-1 plasma viral load at screening visit above 5000 HIV-1 RNA copies/ml

          -  Male, aged above 18 years and less than 65 years of age

          -  Adequate method of birth control

          -  Subject has never received an antiretroviral agent (NRTI, NNRTI, PI, entry inhibitor
             or integrase inhibitor) for the treatment of HIV and agrees not to start
             antiretroviral therapy prior to enrollment or subject has only received a short course
             of treatment for less than 14 days and has been off treatment for at least 8 weeks

          -  Subject has no primary mutation in the reverse transcriptase (RT) gene associated with
             resistance to RT inhibitors and no major mutation in the protease gene associated with
             resistance to PIs determined by genotypic resistance testing at screening

        Exclusion Criteria:

          -  History or suspicion of alcohol or drug abuse which in the Investigator's opinion may
             lead to non-compliance

          -  CD4 count < 350 cells/mm3

          -  Life expectancy of less than 6 months

          -  Receipt of an investigational drug within 30 days prior to the trial drug
             administration

          -  Receipt of any vaccine within 30 days of screening visit

          -  Acute HIV-1 infection (seroconversion illness)

          -  Acute hepatitis A or acute or chronic hepatitis B or C infection

          -  Currently active acquired immune deficiency syndrome (AIDS)-defining illness (Category
             C conditions according to the Centers for Disease Control [CDC] Classification System
             for HIV Infection 1993)

          -  No clinically relevant laboratory abnormalities Renal impairment: serum creatinine >
             1.5 x ULN

          -  Febrile illness within 120 hours prior to dosing

          -  History of severe drug allergy or hypersensitivity

          -  Significant cardiac dysfunction
Clinical trial NCT00102778 (phase 2, status: terminated)
Conditions: infection, human immunodeficiency virus i, hiv infection
ICD codes: Z21, Z21
Drugs: gw873140, kaletra (lopinavir/ritonavir)
SMILES: [H][C@@]1(NC(=O)C2(CCN(CC3=CC=C(OC4=CC=C(C=C4)C(O)=O)C=C3)CC2)N(CCCC)C1=O)[C@H](O)C1CCCCC1, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1
Eligibility criteria:

        Inclusion criteria:

          -  HIV infected, therapy-naive subjects.

          -  Females must be of either non-childbearing age, or have a negative pregnancy test.

          -  All subjects participating in this study should be counseled on the practice of safe
             sex using a proven double barrier method of contraception throughout the study.

          -  Screening lab result of plasma HIV-1 RNA greater than or equal to 50,000 copies/mL and
             CD4 cell count greater than or equal to 100 cells/mm3.

          -  Have CC Chemokine Receptor5-tropic (R5-tropic) or CC Chemokine Receptor5/CXC Chemokine
             Receptor4-tropic (R5/X4-tropic) virus based on viral tropism test at screening visit.

          -  Be treatment-naive, defined as less than or equal to 2 weeks of treatment with a
             protease inhibitor (PI) or an nucleoside reverse transcriptase inhibitor/nucleotide
             reverse transcriptase inhibitor (NRTI/ NtRTI), or less than or equal to 7 days of
             therapy with a non-nucleoside reverse transcriptase inhibitor (NNRTI).

          -  Prior treatment with any entry inhibitor, attachment inhibitor, or fusion inhibitor
             (experimental or approved) is not allowed.

          -  Be able to understand and follow with protocol requirements, instructions and
             protocol-stated restrictions.

          -  Signed and dated written informed consent prior to study entry.

        Exclusion criteria:

          -  No detection of CXC Receptor4-tropic (X4-tropic) virus only, based on viral tropism
             test at screening.

          -  No active Class C AIDS-defining illness.

          -  No laboratory abnormalities at screen.

          -  No significant blood loss prior to study start.

          -  No pregnant or breastfeeding women.

          -  Additional qualifying criteria to be determined by the physician.
Clinical trial NCT01120210 (phase 2, status: completed)
Conditions: heart failure
ICD codes: I50.814, I09.81, I50.82, I50.89, I50.9, T86.22, I11.0
Drugs: jnj-39588146 5 ng/kg/min, jnj-39588146 15 ng/kg/min, jnj-39588146 30 ng/kg/min, placebo, jnj-39588146 5, 15, or 30 ng/kg/min
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have been diagnosed with heart failure

          -  Women must be either postmenopausal or have been surgically sterilized at least 6
             months ago

          -  Males must be willing to use an acceptable birth control method for 3 months after the
             last dose of study medication.

        Exclusion Criteria:

          -  Patients must not have had an heart-assist device or heart transplant or be in
             imminent need of one

          -  Patients must not have had an ischemic attack within the last 6 months or a heart
             attack within the last month

          -  Patients must not have lung disease or congenital heart failure.
Clinical trial NCT01452685 (phase 2, status: completed)
Conditions: endometriosis
ICD codes: N80.8, N80.9, N80.0, N80.1, N80.5, N80.2, N80.3
Drugs: placebo, tak-385, tak-385, tak-385, leuprorelin acetate
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CONC(=O)NC1=CC=C(C=C1)C1=C(CN(C)C)C2=C(S1)N(CC1=C(F)C=CC=C1F)C(=O)N(C2=O)C1=CC=C(OC)N=N1, CONC(=O)NC1=CC=C(C=C1)C1=C(CN(C)C)C2=C(S1)N(CC1=C(F)C=CC=C1F)C(=O)N(C2=O)C1=CC=C(OC)N=N1, CONC(=O)NC1=CC=C(C=C1)C1=C(CN(C)C)C2=C(S1)N(CC1=C(F)C=CC=C1F)C(=O)N(C2=O)C1=CC=C(OC)N=N1, CC(O)=O
Eligibility criteria:

        Inclusion Criteria:

        1. Participants who have completed TAK-385/CCT-101 study

        Exclusion Criteria:

          1. Participants who had an adverse event in TAK-385/CCT-101 study which makes continued
             administration of the study drug difficult

          2. Participants who became unable to comply with the protocol due to onset of a new
             disease, symptom, finding, or aggravation of clinical laboratory findings

          3. Participants in whom investigator deems that the study drug shows no efficacy based on
             the level of pain, menstruation status, and the status of analgesic drug intake in
             TAK-385/CCT-101 study, or that study continuation represents an unacceptable risk

          4. Participants in whom investigator deems that study continuation is difficult due to
             the occurrence of low estrogen symptoms in TAK-385/CCT-101 study which were attributed
             to the pharmacological effects of the study drug taking into account the level and
             frequency of the adverse events etc. as well as the risk-benefit of participants.
Clinical trial NCT01717287 (phase 2, status: completed)
Conditions: hiv infection
ICD codes: Z21
Drugs: raltegravir film-coated tablet, raltegravir chewable tablet, other anti-retroviral therapy
SMILES: CN1C(=O)C(O)=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1, CN1C(=O)C(O)=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  HIV positive

          -  Weight of at least 7 kg

          -  HIV RNA ≥1000 copies/mL within 45 days before study treatment

          -  Participants of reproductive potential and sexually active agree to remain

        abstinent or use (or have their partner use) an acceptable method of birth control
        throughout the study.

        Exclusion Criteria:

          -  Females pregnant or breast-feeding, or expecting to conceive or donate eggs

        during the study; males planning to impregnate or provide sperm donation

        during the study

          -  Use of any non-antiretroviral (ART) investigational agents within one month before
             study treatment

          -  Current (active) diagnosis of acute hepatitis or chronic hepatitis other than stable
             chronic Hepatitis B and/or C

          -  Prior or current use of raltegravir

          -  Use of another experimental HIV-integrase inhibitor

          -  History or current evidence of any condition, therapy, laboratory

        abnormality, or other circumstance that might confound the results of the study, or
        interfere with participation for the full duration of the study

          -  Requires or is anticipated to require any prohibited medications

          -  Use of immunosuppressive therapy within 30 days before beginning

        raltegravir study treatment; short courses of corticosteroids are permitted.

          -  History of malignancy

          -  Current treatment for active tuberculosis infection

          -  Use of recreational or illicit drugs or a recent history (within the

        last year) of drug or alcohol abuse or dependence